(RNAC) Cartesian Therapeutics - Ratings and Ratios
Cell Therapies, mRNA, CAR-T, Autoimmune Treatments, Biotechnology Products
RNAC EPS (Earnings per Share)
RNAC Revenue
Description: RNAC Cartesian Therapeutics
Cartesian Therapeutics Inc. (NASDAQ:RNAC) is a clinical-stage biotechnology company specializing in mRNA cell therapies for treating autoimmune diseases. The companys lead product, Descartes-08, is an autologous mRNA CAR-T therapy targeting B cell maturation antigen (BCMA), currently in Phase 2b clinical trials for various autoimmune diseases, including generalized myasthenia gravis and systemic lupus erythematosus.
From a business perspective, Cartesian Therapeutics has a promising pipeline with Descartes-08 and Descartes-15, another autologous anti-BCMA mRNA CAR-T therapy in development for treating autoimmune diseases and relapsed/refractory multiple myeloma. To evaluate the companys performance, key performance indicators (KPIs) such as research and development (R&D) expenses, cash burn rate, and clinical trial progression can be monitored. As of now, the companys market capitalization stands at $295.10M USD, indicating a relatively small-cap biotechnology firm.
Analyzing the companys valuation, the price-to-earnings (P/E) ratio is 2.13, suggesting a potentially undervalued stock. However, the forward P/E ratio is 25.45, indicating expected growth in earnings. The return on equity (RoE) of 118.52% is exceptionally high, possibly due to the companys focus on R&D and the potential for significant returns on investment in successful therapies. To further assess the companys prospects, investors can track milestones such as clinical trial results, regulatory approvals, and partnerships or collaborations that may impact the stocks performance.
From a trading perspective, the stocks current price is $13.77, with a 20-day simple moving average (SMA) of $10.73 and a 50-day SMA of $10.53, indicating a potential bullish trend. The 200-day SMA is $16.14, suggesting a longer-term bearish trend. The average true range (ATR) is 0.69, representing a 4.99% daily price movement, which can be considered relatively volatile. Investors can monitor these technical indicators to identify potential buy or sell signals.
RNAC Stock Overview
| Market Cap in USD | 255m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2016-06-22 |
RNAC Stock Ratings
| Growth Rating | -87.0% |
| Fundamental | 30.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -49.5% |
| Analyst Rating | 4.25 of 5 |
RNAC Dividends
Currently no dividends paidRNAC Growth Ratios
| Growth Correlation 3m | -33.8% |
| Growth Correlation 12m | -79% |
| Growth Correlation 5y | -92.5% |
| CAGR 5y | -43.10% |
| CAGR/Max DD 3y | -0.51 |
| CAGR/Mean DD 3y | -0.71 |
| Sharpe Ratio 12m | -1.74 |
| Alpha | 0.10 |
| Beta | 0.845 |
| Volatility | 65.52% |
| Current Volume | 52.8k |
| Average Volume 20d | 49.6k |
| Stop Loss | 8.9 (-7.3%) |
| Signal | -1.79 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-36.3m TTM) > 0 and > 6% of Revenue (6% = 61.6k TTM) |
| FCFTA -0.08 (>2.0%) and ΔFCFTA 6.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.7k% (prev 182.4%; Δ 14.5kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.09 (>3.0%) and CFO -33.9m > Net Income -36.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 13.33 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (26.4m) change vs 12m ago 48.65% (target <= -2.0% for YES) |
| Gross Margin 72.12% (prev 99.00%; Δ -26.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.28% (prev 15.56%; Δ -15.28pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -6.57
| (A) 0.39 = (Total Current Assets 163.4m - Total Current Liabilities 12.3m) / Total Assets 388.9m |
| (B) -1.78 = Retained Earnings (Balance) -693.9m / Total Assets 388.9m |
| warn (B) unusual magnitude: -1.78 — check mapping/units |
| (C) -0.21 = EBIT TTM -78.4m / Avg Total Assets 368.3m |
| (D) -1.78 = Book Value of Equity -698.5m / Total Liabilities 391.4m |
| Total Rating: -6.57 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 30.93
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -6.81% = -3.40 |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -5.09 = -2.50 |
| 7. RoE data missing |
| 8. Rev. Trend -73.21% = -5.49 |
| 9. EPS Trend -53.44% = -2.67 |
What is the price of RNAC shares?
Over the past week, the price has changed by -4.86%, over one month by -14.89%, over three months by -6.98% and over the past year by -40.04%.
Is Cartesian Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RNAC is around 5.68 USD . This means that RNAC is currently overvalued and has a potential downside of -40.83%.
Is RNAC a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RNAC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 36.4 | 279.5% |
| Analysts Target Price | 36.4 | 279.5% |
| ValueRay Target Price | 6.1 | -37% |
Last update: 2025-09-12 04:44
RNAC Fundamental Data Overview
CCE Cash And Equivalents = 160.3m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 25.4453
P/S = 248.6156
P/B = 31.2575
Beta = 0.832
Revenue TTM = 1.03m USD
EBIT TTM = -78.4m USD
EBITDA TTM = -75.9m USD
Long Term Debt = 379.2m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 7.58m USD (from shortTermDebt, last quarter)
Debt = 386.7m USD (Calculated: Short Term 7.58m + Long Term 379.2m)
Net Debt = -147.0m USD (from netDebt column, last quarter)
Enterprise Value = 481.5m USD (255.1m + Debt 386.7m - CCE 160.3m)
Interest Coverage Ratio = unknown (Ebit TTM -78.4m / Interest Expense TTM 0.0)
FCF Yield = -6.81% (FCF TTM -32.8m / Enterprise Value 481.5m)
FCF Margin = -3194 % (FCF TTM -32.8m / Revenue TTM 1.03m)
Net Margin = -3534 % (Net Income TTM -36.3m / Revenue TTM 1.03m)
Gross Margin = 72.12% ((Revenue TTM 1.03m - Cost of Revenue TTM 286.0k) / Revenue TTM)
Tobins Q-Ratio = -0.69 (set to none) (Enterprise Value 481.5m / Book Value Of Equity -698.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 386.7m)
Taxrate = 21.0% (US default)
NOPAT = -78.4m (EBIT -78.4m, no tax applied on loss)
Current Ratio = 13.33 (Total Current Assets 163.4m / Total Current Liabilities 12.3m)
Debt / EBITDA = -5.09 (Net Debt -147.0m / EBITDA -75.9m)
Debt / FCF = -11.80 (Debt 386.7m / FCF TTM -32.8m)
Total Stockholder Equity = -7.59m (last 4 quarters mean)
RoA = -9.32% (Net Income -36.3m, Total Assets 388.9m )
RoE = unknown (Net Income TTM -36.3m / Total Stockholder Equity -7.59m)
RoCE = -21.11% (Ebit -78.4m / (Equity -7.59m + L.T.Debt 379.2m))
RoIC = unknown (NOPAT -78.4m, Invested Capital -7.59m, Ebit -78.4m)
WACC = 3.63% (E(255.1m)/V(641.8m) * Re(9.13%)) + (D(386.7m)/V(641.8m) * Rd(0.0%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 16.15%
Discount Rate = 9.13% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -32.8m)
EPS Correlation: -53.44 | EPS CAGR: -61.69% | SUE: 0.16 | # QB: 0
Revenue Correlation: -73.21 | Revenue CAGR: -78.61% | SUE: N/A | # QB: None
Additional Sources for RNAC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle